近年来，使用单克隆抗体的免疫治疗癌症已经展示出临床成功，尤其是在程序化细胞死亡蛋白1（PD-1）和其配体程序化死亡配体1（PD-L1）的应用方面。Dostarlimab是一种免疫检查点抑制剂，通过结合人类PD-1抑制PD-L1和PD-L2的作用以及与适应性免疫的交互作用。近期的临床试验表明，Dostarlimab对子宫内膜癌症病人的不匹配修复缺陷（dMMR）治疗有效，于2021年在美国和欧盟获得批准。本文全面介绍了Dostarlimab的特点、治疗能力以及不同的适应症。Dostarlimab有望成为许多常常给病人的生活质量带来严重后果的癌症治疗的潜在替代品。概述故事是Dostarlimab是如何治愈参加实验临床试验的18名癌症患者的，最终导致其获得美国FDA批准的全面故事。版权所有 © 2023作者。由Elsevier Ltd.出版。保留所有权利。

In recent years, immunotherapy for cancer treatment using monoclonal antibodies has shown clinical success, particularly with programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1). Dostarlimab, an immune checkpoint inhibitor, interacts with adaptive immunity by binding to human PD-1, inhibiting PD-L1 and PD-L2 interactions, and cross-talk with adaptive immunity. Recent clinical trials have shown that dostarlimab is effective in treating mismatch repair deficiency (dMMR) in endometrial cancer patients, leading to its approval in the United States and the European Union in 2021. This article provides a comprehensive overview of dostarlimab, its therapeutic ability, and the different indications for which it is being used. Dostarlimab could serve as a potential alternative to many cancer treatments that frequently have severe consequences on patients' quality of life. Teaser The comprehensive story behind dostarlimab is how it cured all 18 cancer patients who took part in the experimental clinical trial, ultimately leading to its approval by the US FDA.Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.